'I think therefore I am': Improving cognition

Current Opinion in Psychiatry

Volumn 19, Issue 6, 2006, Pages 570-574

  Ritchie, Karen ^a   Portet, Florence ^a  

^a Montpellier 1 University   (France)

Author keywords

Cognitive dysfunction; Decision making; Mild cognitive impairment; Therapy

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; CYANOCOBALAMIN; DIHYDROPYRIDINE DERIVATIVE; DONEPEZIL; GALANTAMINE; GINKGO BILOBA EXTRACT; MEMANTINE; RALOXIFENE; RIVASTIGMINE;

ALZHEIMER DISEASE; ATHEROSCLEROSIS; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CYANOCOBALAMIN DEFICIENCY; DECISION MAKING; DIFFUSE LEWY BODY DISEASE; HUMAN; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; NEUROBIOLOGY; REVIEW; RISK FACTOR; SIDE EFFECT;

COGNITION; COGNITION DISORDERS; DECISION MAKING; DEMENTIA; HUMANS; INFORMED CONSENT; RISK FACTORS; THINKING;

EID: 33749459373     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yco.0000245744.60631.84     Document Type: Review

References (37)

1. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006; (1):CD005593. Cochrane Collaboration: the only comparative analysis to date of the many trials which have been conducted using the three principal cholinergic agents.
2. Hulihan J, Spivey JM. Once-daily formulation of galantamine. J Am Med Dir Assoc 2006; 7:338.
3. Bullock R, Bergman H, Touchon J, et al. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease. Curr Med Res Opin 2006; 3:483-494.
4. Touchon J, Bergman H, Bullock R, et al. Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology. Curr Med Res Opin 2006; 1:49-59.
5. Cacabelos R. Pharmacogenomics and therapeutic prospects in Alzheimer's disease. Expert Opin Pharmacother 2005; 12:1967-1987. Pharmacogenetics is clearly one of the most interesting new avenues for more accurate application of cognitive therapies. This is a very clear overview of possible applications.
6. Green C, Picot J, Loveman E, et al. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderate Alzheimer's disease. Pharmacoeconomics 2005; 23:1271-1282.
7. Areosa SA, Sherriff F, McShane R. Memantine for dementia. Cochrane Database Syst Rev 2006; (2):CD003154.
8. Sleeper RB. Antipsychotic dose-sparing effect with addition of memantine. Ann Pharmacother 2005; 39:1573-1576.
9. Shearman E, Rossi S, Szasz B, et al. Changes in cerebral neurotransmitters and metabolites induced by acute donepezil and memantine administrations: a microdialysis study. Brain Res Bull 2006; 69:204-213.
10. Stephenson VC, Heyding RA, Weaver DF. The 'promiscuous drug concept' with applications to Alzheimer's disease. FEBS Lett 2005; 579:1338-1342.
11. Malouf M, Grimley EJ, Areosa SA. Folic acid with or without vitamin B12 for cognition and dementia. Cochrane Database Syst Rev 2003; (4):CD004514.
12. Maxwell CJ, Hicks MS, Hogan DB, et al. Supplemental use of antioxidant vitamins and subsequent risk of cognitive decline and dementia. Dement Geriatr Cogn Disord 2005; 20:45-51.
13. Huang TL, Zandi PP, Tucker KL, et al. Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon 4. Neurology 2005; 65:1409-1414.
14. Rea TD, Breitner JC, Psaty BM, et al. Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol 2005; 62:1047-1051.
15. Ancelin ML, Ritchie K. Lifelong endocrine fluctuations and related cognitive disorders. Curr Pharm Des 2005; 11:4229-4252.
16. Yaffe K, Krueger K, Cummings SR, et al. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry 2005; 162:645-647.
17. Schneider LS, DeKosky ST, Farlow MR, et al. A randomized double-blind placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type. Curr Alzheimer Res 2005; 5:541-551.
18. Dekosky ST, Fitzpatrick A, Ives DG, et al. The Ginko Evaluation of Memory (GEM) study: design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia. Contemp Clin Trials 2006; 27:238-253.
19. Yu J, Zhang X, Liu C, et al. Effect of acupuncture treatment on vascular dementia. Neurol Res 2006; 28:97-103.
20. Orrell M, Spector A, Thorgrimsen L, Woods B. A pilot study examining the effectiveness of maintenance Cognitive Stimulation Therapy for people with dementia. Int J Geriatr Psychiatry 2005; 20:446-451. Cognitive therapies are often recommended to treat cognitive deficits in dementia but adequate randomized controlled trials are rare.
21. Roman GC, Kalaria RN. Vascular determinants of cholinergic deficits in Alzheimer disease and vascular dementia. Neurobiol Aging 2005; Nov 18 [Epub ahead of print].
22. Roman GC, Wilkinson DG, Doody RS, et al. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. Dement Geriatr Cogn Disord 2005; 20:338-344.
23. Zanchetti A, Bond MG, Hennig M, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Circulation 2002; 106:2422-2427.
24. Sabbagh MN, Hake AM, Ahmed S, Farlow MR. The use of memantine in dementia with Lewy bodies. J Alzheimer's Dis 2005; 4:285-289.
25. Deramecourt V, Bombois S, Maurage CA, et al. Biochemical staging of synucleinopathy and amyloid deposition in dementia with Lewy bodies. J Neuropathol Exp Neurol 2006; 65:278-288.
26. Sever P. The SCOPE trial. Study on Cognition and Prognosis in the Elderly. J Renin Angiotensin Aldosterone Syst 2002; 3:61-62.
27. Zanchetti A, Elmfeldt D. Findings and implications of the Study on Cognition and Prognosis in the Elderly (SCOPE). Blood Press 2006; 15:71-79.
28. ALLHAT Collaborative Research Group. Major outcomes in high risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs. diuretic. JAMA 2002; 288:2981-2997.
29. Biessels GJ, Staekenbourg S, Brunner E, et al. Risk of dementia in diabetes mellitus. Lancet Neurol 2006; 5:64-74. A rigorous meta-analysis demonstrating diabetes as a risk factor for cognitive degeneration linked to both Alzheimer's disease (eight of 13 studies) and VaD (six of nine studies).
30. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80 per cent. BMJ 2003; 326:1419-1423.
31. Jelic V, Winblad B. Treatment of mild cognitive impairment: rationale, present and future strategies. Acta Neurol Scand 2003; 107:83-93.
32. Dekosky ST, Ikonomovic MD, Styren SD. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 2002; 51:145-155.
33. Petersen R, Thomas R, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive disorder. N Engl J Med 2005; 352:2379-2388.
34. Ancelin ML, Artero S, Portet F, et al. Nondegenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 2006; 332:455-459.
35. Hirschman KB, Joyce CM, James BD, et al. Would caregivers of Alzheimer's disease patients involve their relative in a decision to use an AD-slowing medication? Am J Geriatr Psychiatry 2005; 11:1014-1021.
36. Hirschman KB, Joyce CM, James BD, et al. Do Alzheimer's disease patients want to participate in a treatment decision, and would their care-givers let them? Gerontologist 2005; 3:381-388.
37. Hirschman KB, Xie SX, Feudtner C, Karlawish JH. How does an Alzheimer's disease patient's role in medical decision making change over time? J Geriatr Psychiatry Neurol 2004; 2:55-60.